Statement issued by the company (Announcement)<\/p>\n
Boehringer Ingelheim<\/strong> today announces the start of a Phase II clinical trial<\/strong> evaluating its investigational triple GLP-1\/GIP\/NPY2 receptor agonist, BI 3034701<\/strong>, in patients with obesity and overweight.1<\/sup> The trial represents a significant milestone for Boehringer\u2019s cardiometabolic and obesity pipeline, which aims to address obesity as a central driver of interconnected cardiovascular, renal and metabolic conditions.5,6<\/sup><\/p>\n Obesity is a complex, chronic disease that impacts more than 1 in 8 people worldwide in many different ways, and can have serious long-term consequences.7,8 <\/sup>Due to the heterogeneity of the disease, different mechanisms are needed to address different patient needs, disease stages, and risk profiles.8,9<\/sup><\/p>\n BI 3034701 is a potential first-in-class triple agonist designed to activate the GLP\u20111, GIP, and NPY2 receptors.1<\/sup> By engaging these three complementary biological pathways, the molecule aims to address obesity through simultaneously targeting the regulation of body weight and metabolism.2,3,4<\/sup> While the impact of GLP-1 and GIP on satiety, weight, and metabolic regulation is well established,2<\/sup> NPY2R agonism provides a potentially differentiated mechanism that is still being investigated. Based on scientific literature, activation of the NPY2 receptor modulates central hunger signaling, while its impact on broader eating behavior remains to be fully elucidated.4<\/sup><\/p>\n In Phase I studies, BI 3034701 demonstrated a generally favorable safety and tolerability profile,10<\/sup> a key factor in advancing the program into its next phase of clinical development. The Phase II study is designed to evaluate the molecule in people living with obesity and overweight, including dose finding and broader clinical evaluation of efficacy and safety.1 <\/sup><\/p>\n \u201cThe obesity treatment landscape is rapidly expanding,\u00a0with a\u00a0need\u00a0to target\u00a0a broader variety of therapeutic mechanisms given that obesity is a heterogeneous\u00a0disease. This approach\u00a0may better\u00a0enable\u00a0healthcare providers to move towards matching the right treatment to the right patient at the right time,\u201d said Dr Ania Jaestreboff<\/strong> MD, PhD,\u00a0professor at Yale School of Medicine and Director of the Yale Obesity Research\u00a0Center (Y-Weight)<\/strong>.<\/p>\n \u201cAt Boehringer Ingelheim, we are working towards a future where earlier, multi-pathway intervention leads to long-term outcomes that prevent the progression of interconnected cardiometabolic diseases,\u201d said Shashank Deshpande<\/strong>, Chairman of the Board of Managing Directors and Head of Human Pharma, Boehringer Ingelheim. \u201cIn the future, we expect obesity care to become much more differentiated, and with BI 3034701, we aim to go beyond short-term weight loss and address both the biological and behavioral drivers of obesity.\u201d<\/p>\n BI 3034701 is part of a broader portfolio of therapies being developed for people living with obesity or obesity and connected metabolic health conditions, which has multiple approaches under investigation, including survodutide, a dual glucagon\/GLP-1 agonist. Results from Phase III trials of survodutide were recently presented\u00a0at\u00a0American Diabetes Association\u2019s (ADA) 2026 Scientific\u00a0Sessions.11<\/sup> Boehringer Ingelheim\u2019s pipeline\u00a0across obesity and liver health also\u00a0includes additional next-generation therapies and experimental approaches including oral treatment options.12<\/sup><\/p>\n BI 3034701 was developed in cooperation with Gubra. Boehringer Ingelheim is solely responsible for further development and global commercialization of BI 3034701.<\/p>\n In 2016, more than 1.9 billion adults lived with overweight \u2014 defined as a body mass index (BMI) of 25 or more.13<\/sup> Of these, over 650 million were living with obesity \u2014 defined as a BMI of 30 or more.13<\/sup> More than one billion people around the world are living with obesity today (1 in 8 of us) \u2014 and by 2030, that number could be more than double what it was in 2010.14<\/sup> Overweight and obesity are complex chronic conditions involving abnormal or excessive fat accumulation that present a risk to a person\u2019s overall health.8 <\/sup><\/p>\n Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry\u2019s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,300 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at www.boehringer-ingelheim.com.<\/a><\/p>\n This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.<\/p>\nNotes to Editors<\/u><\/h2>\n
About BI 3034701<\/h3>\n
About obesity and overweight<\/h3>\n
About Boehringer Ingelheim<\/h3>\n
Boehringer Ingelheim\u2019s Intended Audiences Notice<\/h3>\n
References<\/h2>\n
\n
Attachment<\/h2>\n